Compare SFST & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | GYRE |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 565.5M | 625.6M |
| IPO Year | 2012 | 2004 |
| Metric | SFST | GYRE |
|---|---|---|
| Price | $59.35 | $4.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $68.75 | $18.67 |
| AVG Volume (30 Days) | 67.3K | ★ 144.2K |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.76 | N/A |
| EPS | ★ 3.68 | N/A |
| Revenue | ★ $6,282,000.00 | $275,000.00 |
| Revenue This Year | $23.97 | N/A |
| Revenue Next Year | $17.69 | $27.49 |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $46.80 | $4.27 |
| 52 Week High | $65.09 | $9.14 |
| Indicator | SFST | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 36.84 |
| Support Level | $58.70 | N/A |
| Resistance Level | $60.83 | $7.37 |
| Average True Range (ATR) | 1.93 | 0.55 |
| MACD | -0.11 | -0.18 |
| Stochastic Oscillator | 9.16 | 21.73 |
Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.